Unknown Author
January 23, 2026
Sidley Represents Nektar Therapeutics in Its Sale of Its Manufacturing Facility and Reagent Supply Business

1 min
AI-made summary
- Sidley is advising Nektar Therapeutics on the US$90 million sale of its manufacturing facility and reagent supply business to Ampersand Capital Partners
- The transaction is intended to streamline Nektar Therapeutics’ operations as the company focuses on expanding its core research and development programs in immunology
- The Sidley legal team is led by Daniel J
- Belke, Tommy Tsao, Joshua T
- Hofheimer, Lauren G
- Grau, Antoinette R
- Petkov, Lauren E
- Dunn, and Sabrina K
- Glavota.
Sidley is representing Nektar Therapeutics in its US$90 million sale of its manufacturing facility and reagent supply business to Ampersand Capital Partners. The sale will help to streamline Nektar Therapeutics’ future operations as it looks to expand its development of core research and development programs in immunology. The Sidley team is being led by Daniel J. Belke and Tommy Tsao (M&A and Private Equity) and Joshua T. Hofheimer and Lauren G. Grau (Technology and Life Sciences Transactions), and includes Antoinette R. Petkov and Lauren E. Dunn (M&A and Private Equity) and Sabrina K. Glavota (Technology and Life Sciences Transactions).~~Sidley is representing Nektar Therapeutics in its US$90 million sale of its manufacturing facility and reagent supply business to Ampersand Capital Partners. The sale will help to streamline Nektar Therapeutics’ future operations as it looks to expand its development of core research and development programs in immunology. The Sidley team is being led by Daniel J. Belke and Tommy Tsao (M&A and Private Equity) and Joshua T. Hofheimer and Lauren G. Grau (Technology and Life Sciences Transactions), and includes Antoinette R. Petkov and Lauren E. Dunn (M&A and Private Equity) and Sabrina K. Glavota (Technology and Life Sciences Transactions).
Article Author
Unknown Author
The Sponsor
